S
Sarah Elitzur
Researcher at Tel Aviv University
Publications - 59
Citations - 1060
Sarah Elitzur is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 42 publications receiving 662 citations. Previous affiliations of Sarah Elitzur include Children's Medical Center of Dallas.
Papers
More filters
Journal ArticleDOI
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Thomas B. Alexander,Thomas B. Alexander,Zhaohui Gu,Ilaria Iacobucci,Kirsten Dickerson,John K. Choi,Beisi Xu,Debbie Payne-Turner,Hiroki Yoshihara,Mignon L. Loh,John T. Horan,Barbara Buldini,Giuseppe Basso,Sarah Elitzur,Valerie de Haas,C. Michel Zwaan,Allen Eng Juh Yeoh,Dirk Reinhardt,Daisuke Tomizawa,Nobutaka Kiyokawa,Tim Lammens,Barbara De Moerloose,Daniel Catchpoole,Hiroki Hori,Anthony V. Moorman,Andrew S. Moore,Ondrej Hrusak,Soheil Meshinchi,Soheil Meshinchi,Etan Orgel,Meenakshi Devidas,Michael J. Borowitz,Brent L. Wood,Nyla A. Heerema,Andrew Carrol,Yung-Li Yang,Malcolm A. Smith,Tanja M. Davidsen,Leandro C. Hermida,Patee Gesuwan,Marco A. Marra,Yussanne Ma,Andrew J. Mungall,Richard A. Moore,Steven J.M. Jones,Marcus B. Valentine,Laura J. Janke,Jeffrey E. Rubnitz,Ching-Hon Pui,Liang Ding,Yu Liu,Jinghui Zhang,Kim E. Nichols,James R. Downing,Xueyuan Cao,Lei Shi,Stanley Pounds,Scott Newman,Deqing Pei,Jaime M. Guidry Auvil,Daniela S. Gerhard,Stephen P. Hunger,Hiroto Inaba,Charles G. Mullighan +63 more
TL;DR: A large-scale genomics study shows that the cell of origin and founding mutations determine disease subtype and lead to the expression of multiple haematopoietic lineage-defining antigens in mixed phenotype acute leukaemia.
Journal ArticleDOI
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment.
Ondrej Hrusak,Tomas Kalina,Joshua Wolf,Adriana Balduzzi,Massimo Provenzi,Carmelo Rizzari,Susana Rives,María del Pozo Carlavilla,Maria E.V. Alonso,Nerea Domínguez-Pinilla,Jean-Pierre Bourquin,Kjeld Schmiegelow,Andishe Attarbaschi,Pernilla Grillner,Karin Mellgren,Jutte van der Werff ten Bosch,Rob Pieters,Triantafyllia Brozou,Arndt Borkhardt,Gabriele Escherich,Melchior Lauten,Martin Stanulla,Owen P. Smith,Allen Eng Juh Yeoh,Sarah Elitzur,Ajay Vora,Chi Kong Li,Hany Ariffin,A Kolenova,Luciano Dalla-Pozza,Roula Farah,Jelena Lazic,Atsushi Manabe,Jan Styczyński,Gabor G. Kovacs,Gábor Ottóffy,Maria S. Felice,Barbara Buldini,Valentino Conter,Jan Stary,Martin Schrappe +40 more
TL;DR: Even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19, and the intensity of preventive measures should not cause delays or obstructions in oncological treatment.
Journal ArticleDOI
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
Jean Donadieu,Islam Amine Larabi,Mathilde Tardieu,Johannes Visser,Caroline Hutter,Elena Sieni,Nabil Kabbara,Mohamed Barkaoui,Jean Miron,François Chalard,Paul Milne,Julien Haroche,Fleur Cohen,Zofia Hélias-Rodzewicz,Nicolas Simon,Mathilde Jehanne,Alexandra Kolenova,Anne Pagnier,Nathalie Aladjidi,Pascale Schneider,Geneviève Plat,Anne Lutun,Anne Sonntagbauer,Thomas Lehrnbecher,Alina Ferster,Viktoria Efremova,Martina Ahlmann,Laurence Blanc,James Nicholson,Anne Lambilliote,Houda Boudiaf,Andrej Lissat,Karel Svojgr,Fanette Bernard,Sarah Elitzur,Michal Golan,Dmitriy Evseev,Michael Maschan,Ahmed Idbaih,Olga Slater,Milen Minkov,Valérie Taly,Matthew Collin,Jean-Claude Alvarez,Jean-François Emile,Sébastien Héritier +45 more
TL;DR: VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH and none of the various empirical therapies used for maintenance could eradicate the BRAFv600E clone.
Journal ArticleDOI
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation
Joachim B. Kunz,Tobias Rausch,Obul Reddy Bandapalli,Juliane Eilers,Paulina Pechanska,Stephanie Schuessele,Yassen Assenov,Adrian M. Stütz,Renate Kirschner-Schwabe,Jana Hof,Cornelia Eckert,Arend von Stackelberg,Martin Schrappe,Martin Stanulla,Rolf Koehler,Smadar Avigad,Sarah Elitzur,Rupert Handgretinger,Vladimir Benes,Joachim Weischenfeldt,Jan O. Korbel,Martina U. Muckenthaler,Andreas E. Kulozik +22 more
TL;DR: Mechanisms that drive progression of pediatric T-cell acute lymphoblastic leukemia to relapse are identified and may explain the characteristic treatment resistance of this condition.
Journal ArticleDOI
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia
Ondrej Hrusak,Valerie de Haas,Jitka Stancikova,Barbora Vakrmanova,Iveta Janotova,Ester Mejstrikova,Vaclav Capek,Jan Trka,Marketa Zaliova,Ales Luks,Kirsten Bleckmann,Anja Möricke,Julie Irving,Benigna Konatkowska,Thomas B. Alexander,Hiroto Inaba,Kjeld Schmiegelow,Kjeld Schmiegelow,Simone Stokley,Zuzana Zemanova,Anthony V. Moorman,Jorge Rossi,Maria S. Felice,Luciano Dalla-Pozza,Jessa Morales,Michael Dworzak,Barbara Buldini,Giuseppe Basso,Myriam Campbell,Myriam Campbell,Maria Elena Cabrera,Maria Elena Cabrera,Neda Marinov,Neda Marinov,Sarah Elitzur,Shai Izraeli,Drorit Luria,Tamar Feuerstein,Alexandra Kolenova,Peter Svec,Olena Kreminska,Karen R. Rabin,Sophia Polychronopoulou,Elaine da Costa,Hanne Vibeke Marquart,Antonis Kattamis,Richard Ratei,Dirk Reinhardt,John K. Choi,Martin Schrappe,Jan Stary +50 more
TL;DR: In this article, the authors report a large cohort of children with ambiguous lineage leukemia (ALAL) and propose a treatment strategy, which includes acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) and acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2%).